This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Becton, Dickinson Hits at a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Wright Medical Strong Overseas, Back Order Issues Persist
by Zacks Equity Research
Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.
Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children
by Zacks Equity Research
Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.
Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 1.39% and 1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Abiomed Gets CDSCO Nod for Impella Heart Pumps in India
by Zacks Equity Research
Abiomed's (ABMD) Impella gets regulatory approval in India; prospects in APAC look upbeat.
Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.
Stryker (SYK) Beats on Q2 Earnings, International Sales Up
by Zacks Equity Research
Stryker (SYK) gains from solid segmental performance in Q2.
Medidata (MDSO) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental performance in Q2; banks on strategic buyouts.
Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.
OPKO Health's RAYALDEE Gets Approval in Canada to Treat CKD
by Zacks Equity Research
OPKO Health's (OPK) partner VFMCRP gets regulatory nod from Health Canada to market flagship RAYALDEE; benefits patients diagnosed with chronic kidney disease.
Intuitive Surgical's FDA Approval for SureForm to Aid Surgery
by Zacks Equity Research
Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.
MASI or STE: Which Is a Better Investment Option Right Now?
by Zacks Equity Research
Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.
Integer Holdings Offloads AS&O, Focuses on Cardiac Units
by Zacks Equity Research
Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.
MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE
by Zacks Equity Research
Masimo's (MASI) Eve with Rad-97 Pulse CO-Oximeter to be integrated in nine hospitals across UAE for CCHD screening in newborns.
Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring
by Zacks Equity Research
Masimo (MASI) along with Thermomedics launches TIR-1 in the United States, market prospects look solid.
Why Is Masimo (MASI) Up 9.2% Since Its Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance
by Zacks Equity Research
Masimo's (MASI) impressive growth in overseas markets drives the bottom line in Q1. New products, including NomoLine capnography and O3 organ oximetry, are major catalysts.
Medical Product Stock Earnings on May 2: CERN, ABC & More
by Zacks Equity Research
Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.
Masimo Gets CE Mark for NomoLine, Expands in Capnography
by Zacks Equity Research
Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.
Why Masimo (MASI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) can be a harbinger of outperformance and a signal for a strong earnings profile on the back of solid Zacks rank and positive earnings ESP.
Masimo (MASI) Launches UniView, Improves Patient Safety
by Zacks Equity Research
Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides on solid earnings results and a wide array of products.